Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD

Eur Respir J. 2018 Oct 4;52(4):1801020. doi: 10.1183/13993003.01020-2018. Print 2018 Oct.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Aged
  • Female
  • Health Status
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / administration & dosage
  • Piperidines / therapeutic use*
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Receptors, Interleukin-8B / antagonists & inhibitors*
  • Sulfones / therapeutic use*
  • Treatment Outcome

Substances

  • Piperidines
  • Receptors, Interleukin-8B
  • Sulfones
  • Omeprazole
  • danirixin

Associated data

  • ClinicalTrials.gov/NCT02130193